Patients taking Elmiron to treat interstitial cystitis should be aware that the medication recently received updated language to its label reflecting an enhanced risk of and link to a form of eye disease. Known as pigmentary maculopathy, the condition causes the patient’s eyes to create additional excess blood capillaries or spots on the retina. This, in turn, leads to losses in vision in the central areas ...
continue reading...Elmiron Gets New Language Added to Label
Posted July 28, 2020 in Product News and Recalls